Home

Pfizer (PFE)

25.35
-0.30 (-1.17%)
NYSE · Last Trade: Jul 14th, 5:32 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close25.65
Open25.58
Bid25.35
Ask25.37
Day's Range25.34 - 25.63
52 Week Range20.92 - 31.54
Volume25,888,710
Market Cap142.13B
PE Ratio (TTM)18.37
EPS (TTM)1.4
Dividend & Yield1.720 (6.79%)
1 Month Average Volume39,599,520

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlookbenzinga.com
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.
Via Benzinga · July 14, 2025
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?benzinga.com
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.
Via Benzinga · July 14, 2025
3 S&P 500 Stocks in Hot Water
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · July 14, 2025
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimonybenzinga.com
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.
Via Benzinga · July 11, 2025
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Leviesbenzinga.com
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via Benzinga · July 11, 2025
GSK Stock Gains As Flu Vaccine Rollout Begins And US Recovers From Most Severe Season In 15 Yearsstocktwits.com
Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré syndrome.
Via Stocktwits · July 10, 2025
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Studybenzinga.com
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.
Via Benzinga · July 10, 2025
Should Politicians Be Allowed to Trade Stocks? The Big Debate
A growing chorus of lawmakers, ethics watchdogs, and concerned citizens are reigniting a high-stakes debate: Should U.S. politicians be allowed to buy and sell stocks while in office? Amidst rising public distrust and a series of high-profile investigations into lawmakers' financial dealings, calls to ban or heavily restrict stock
Via MarketMinute · July 10, 2025
An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?'benzinga.com
Via Benzinga · July 10, 2025
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Monthsbenzinga.com
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute.
Via Benzinga · July 10, 2025
A Message to All Investors From Motley Fool CEO Tom Gardnerfool.com
Via The Motley Fool · July 10, 2025
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) at high risk for metastasis.
By Pfizer Inc. · Via Business Wire · July 10, 2025
This Is the No. 1 Ultra-High-Yield Dividend Stock Held by Retail Investors on Robinhood -- and It's Not Even Closefool.com
The supercharged income stock coveted most by everyday investors is sporting a 5.14% yield.
Via The Motley Fool · July 10, 2025
Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiarybenzinga.com
Warren Buffett is indirectly invested in high-dividend yield stocks via Berkshire Hathaway Inc.'s subsidiary New England Asset Management.
Via Benzinga · July 9, 2025
These S&P500 stocks are the most active in today's sessionchartmill.com
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · July 8, 2025
3 Disappointing Blue Chip Stocks That Have Crashed as Much as 87% in 10 Yearsfool.com
Via The Motley Fool · July 8, 2025
Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaroundbenzinga.com
While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.
Via Benzinga · July 7, 2025
Top 5 Undervalued Dividend Stocks With Strong Payout Potentialmarketbeat.com
Seemingly undervalued dividend stocks, such as BAC, F, MO, VZ, and PFE, offer a rare combination of strong yields and attractive valuations.
Via MarketBeat · July 7, 2025
3 No-Brainer Stocks to Buy in Julyfool.com
Via The Motley Fool · July 7, 2025
Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch.fool.com
Via The Motley Fool · July 7, 2025
The Best Dividend Stocks I'd Buy Right Nowfool.com
Via The Motley Fool · July 5, 2025
2 Stocks to Buy With Less Than $50fool.com
Via The Motley Fool · July 4, 2025
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Reportbenzinga.com
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .
Via Benzinga · July 4, 2025
Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028fool.com
The parabolic ascent of artificial intelligence (AI) superstar Palantir Technologies may be short-lived.
Via The Motley Fool · July 4, 2025
3 Safe-and-Steady Stocks on Our Watchlist
By avoiding big swings, low-volatility stocks let investors focus on long-term fundamentals. These stocks may not be up 100% in a single year, but they offer a measured approach to building wealth over time.
Via StockStory · July 4, 2025